SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point moves up on getting Colombia's INVIMA approval for Softgel Capsules division

06 May 2024 Evaluate

Caplin Point Laboratories is currently trading at Rs. 1301.70, up by 2.90 points or 0.22% from its previous closing of Rs. 1298.80 on the BSE.

The scrip opened at Rs. 1300.00 and has touched a high and low of Rs. 1321.00 and Rs. 1277.85 respectively. So far 7824 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1617.80 on 19-Feb-2024 and a 52 week low of Rs. 673.10 on 05-May-2023.

Last one week high and low of the scrip stood at Rs. 1370.15 and Rs. 1277.85 respectively. The current market cap of the company is Rs. 9836.35 crore.

The promoters holding in the company stood at 70.62%, while Institutions and Non-Institutions held 4.43% and 24.95% respectively.

Caplin Point Laboratories has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3 and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1772.50 6.05 (0.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×